A detailed history of Raymond James & Associates transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Raymond James & Associates holds 15,789 shares of PRCT stock, worth $1.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,789
Previous 12,295 28.42%
Holding current value
$1.54 Million
Previous $751,000 68.31%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$56.31 - $84.99 $196,747 - $296,955
3,494 Added 28.42%
15,789 $1.26 Million
Q2 2024

Jul 19, 2024

BUY
$45.73 - $69.19 $107,145 - $162,112
2,343 Added 23.54%
12,295 $751,000
Q1 2024

Apr 22, 2024

BUY
$40.38 - $50.75 $401,861 - $505,064
9,952 New
9,952 $491,000

Others Institutions Holding PRCT

About PROCEPT BioRobotics Corp


  • Ticker PRCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 44,592,300
  • Market Cap $4.34B
  • Description
  • PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...
More about PRCT
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.